EW - Bathi operasional sadurunge amortisasi Edwards

Edwards Lifesciences business is protected by the low elasticity of demand for cardiac surgery, although a slowdown in TAVR procedure rates across developed countries is constraining revenue. The cash EBITDA figure on this GURU.Markets chart clearly demonstrates current operating efficiency, where 2090.04 represents the latest metric reading. The issuer's success is based on its dominance in the valve replacement segment, FDA approvals, and patent protection.

Edwards Lifesciences dominance in the TAVR valve segment is directly reflected in the dynamics of the company's total operating profit. This indicator captures the actual cash flow from core operations before accounting adjustments. The calculation excludes the impact of depreciation and debt obligations, exposing the real efficiency of the business model. Daily monitoring allows for the exclusion of one-time write-offs, confirming revenue stability. This makes the asset attractive for long-term institutional investors.